Insider Sale: Chief Medical Officer of $ARVN Sells 8,658 Shares

Noah Berkowitz, the Chief Medical Officer of $ARVN, sold 8,658 shares of the company on 03-18-2025 for an estimated $74,372. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.3% of their shares of this class of stock. Following this trade, they now own 110,023 shares of this class of $ARVN stock.

$ARVN Insider Trading Activity

$ARVN insiders have traded $ARVN stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:

• JOHN G HOUSTON (President and CEO) has made 0 purchases and 2 sales selling 31,338 shares for an estimated $523,880.
• IAN TAYLOR (President, R&D) has made 0 purchases and 2 sales selling 9,020 shares for an estimated $150,752.
• NOAH BERKOWITZ (Chief Medical Officer) sold 8,658 shares for an estimated $74,372
• ANGELA M CACACE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 4,207 shares for an estimated $70,238.
• DAVID K LOOMIS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 1,445 shares for an estimated $26,730.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ARVN Hedge Fund Activity

We have seen 102 institutional investors add shares of $ARVN stock to their portfolio, and 106 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• PARADIGM BIOCAPITAL ADVISORS LP removed 2,339,961 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $44,857,052
• T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,208,234 shares (+inf%) to their portfolio in Q4 2024, for an estimated $42,331,845
• UBS GROUP AG added 1,566,881 shares (+332.3%) to their portfolio in Q4 2024, for an estimated $30,037,108
• FMR LLC removed 1,324,777 shares (-45.9%) from their portfolio in Q4 2024, for an estimated $25,395,975
• BRAIDWELL LP removed 1,284,472 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,623,328
• COMMODORE CAPITAL LP removed 1,200,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $23,004,000
• RTW INVESTMENTS, LP added 551,979 shares (+19.8%) to their portfolio in Q4 2024, for an estimated $10,581,437

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ARVN Analyst Ratings

Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• BMO Capital issued a "Outperform" rating on 03/12/2025
• Wells Fargo issued a "Overweight" rating on 03/12/2025
• BTIG issued a "Buy" rating on 12/10/2024
• Leerink Partners issued a "Outperform" rating on 11/19/2024

To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.

$ARVN Price Targets

Multiple analysts have issued price targets for $ARVN recently. We have seen 7 analysts offer price targets for $ARVN in the last 6 months, with a median target of $40.0.

Here are some recent targets:

• An analyst from Morgan Stanley set a target price of $12.0 on 03/13/2025
• Etzer Darout from BMO Capital set a target price of $20.0 on 03/12/2025
• Derek Archila from Wells Fargo set a target price of $26.0 on 03/12/2025
• Jeet Mukherjee from BTIG set a target price of $69.0 on 12/10/2024
• Christopher Liu from Leerink Partners set a target price of $62.0 on 11/19/2024
• Matthew Biegler from Oppenheimer set a target price of $40.0 on 10/31/2024
• Bradley Canino from Stifel Nicolaus set a target price of $63.0 on 10/21/2024

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.